Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: levormeloxifene and raloxifene

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Climacteric

• Publication date

  2003-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/cmt.6.2.159.167PMID 12841887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.

  2004cited by this paper
• Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

  2002cited by this paper
• Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

  2001cited by this paper
• Design and methods of the Raloxifene Use for The Heart (RUTH) study.

  2001cited by this paper
• Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.

  2001cited by this paper
• Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial

  2000cited by this paper
• Molecular mechanisms of selective estrogen receptor modulator (SERM) action.

  2000cited by this paper
• Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.

  2000cited by this paper
• Medical statistics − a commonsense approach

  2000cited by this paper
• Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat.

  2000cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.

  1998cited by this paper
• Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

  1998cited by this paper
• Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

  1998cited by this paper
• A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits.

  1997cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

  1996cited by this paper
• Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

  1994cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆

  1991cited by this paper
• Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

  1987cited by this paper
• LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN

  1976cited by this paper
• Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment.

  1976cited by this paper

• Levormeloxifene - a non-hormonal woman-centric oral contraceptive under development: a comprehensive review

  2025cites this paper
• High Cholesterol Deteriorates Bone Health: New Insights into Molecular Mechanisms

  2015cites this paper
• Estrogen receptors as therapeutic targets in breast cancer.

  2006cites this paper
• Silk decorations: controversy and consensus

  2006cites this paper
• What can be learned from the levormeloxifene experience?

  2006cites this paper
• Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women

  2005cites this paper
• Raloxifeno, lipoproteínas y eventos cardiovasculares. Revisión de la literatura

  2005cites this paper
• Effect of raloxifene on lowering lipid parameters in patients with osteoporosis.

  2003cites this paper